Ionis said it will present four oral analyses from the Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia at upcoming ADA, NLA and ENDO 2026 meetings, while the drug’s U.S. review continues under FDA Priority Review.
Ionis Pharmaceuticals said it will present new analyses from its Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia at several upcoming cardiometabolic meetings.
The company said the data will be shared in four oral presentations at the American Diabetes Association Scientific Sessions in New Orleans, the National Lipid Association Scientific Sessions in Chicago and ENDO 2026 in Chicago. Ionis said the analyses expand understanding of olezarsen across different patient and treatment backgrounds.
The release comes as the company’s marketing application for olezarsen in severe hypertriglyceridemia remains under FDA Priority Review, with a target action date of June 30, 2026.
What comes next
The first of the three congresses begins June 5, followed by NLA Scientific Sessions on June 11 and ENDO 2026 on June 13. Any public presentation details from those meetings could further clarify how Ionis is positioning the drug ahead of the FDA decision.
Olezarsen is also known as Tryngolza.
Revision note
Initial automated publication.